Katherine Karakasis

2.1k total citations
44 papers, 1.0k citations indexed

About

Katherine Karakasis is a scholar working on Reproductive Medicine, Oncology and Cancer Research. According to data from OpenAlex, Katherine Karakasis has authored 44 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Reproductive Medicine, 24 papers in Oncology and 10 papers in Cancer Research. Recurrent topics in Katherine Karakasis's work include Ovarian cancer diagnosis and treatment (27 papers), PARP inhibition in cancer therapy (16 papers) and Cancer Genomics and Diagnostics (8 papers). Katherine Karakasis is often cited by papers focused on Ovarian cancer diagnosis and treatment (27 papers), PARP inhibition in cancer therapy (16 papers) and Cancer Genomics and Diagnostics (8 papers). Katherine Karakasis collaborates with scholars based in Canada, United States and Australia. Katherine Karakasis's co-authors include Amit M. Oza, Michelle Wilson, Michelle McMullen, Ainhoa Madariaga, Stéphanie Lheureux, Blaise Clarke, Valerie Bowering, Trevor J. Pugh, Stéphanie Lheureux and Julia V. Burnier and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and The Lancet Oncology.

In The Last Decade

Katherine Karakasis

40 papers receiving 988 citations

Peers

Katherine Karakasis
Eleonora Ghisoni Italy
Thomas J. Herzog United States
Marilena Di Napoli Italy
Antonella Pietragalla Italy
Asima Mukhopadhyay India
Angela George United Kingdom
Katherine C. Kurnit United States
Ainhoa Madariaga Spain
Rowan Miller United Kingdom
Laure Favier France
Eleonora Ghisoni Italy
Katherine Karakasis
Citations per year, relative to Katherine Karakasis Katherine Karakasis (= 1×) peers Eleonora Ghisoni

Countries citing papers authored by Katherine Karakasis

Since Specialization
Citations

This map shows the geographic impact of Katherine Karakasis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Katherine Karakasis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Katherine Karakasis more than expected).

Fields of papers citing papers by Katherine Karakasis

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Katherine Karakasis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Katherine Karakasis. The network helps show where Katherine Karakasis may publish in the future.

Co-authorship network of co-authors of Katherine Karakasis

This figure shows the co-authorship network connecting the top 25 collaborators of Katherine Karakasis. A scholar is included among the top collaborators of Katherine Karakasis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Katherine Karakasis. Katherine Karakasis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Colombo, Ilaria, et al.. (2023). Chasing Immune Checkpoint Inhibitors in Ovarian Cancer: Novel Combinations and Biomarker Discovery. Cancers. 15(12). 3220–3220. 29 indexed citations
2.
Lee, Yeh Chen, Valerie Bowering, Sarah E. Ferguson, et al.. (2022). Management of Malignant Bowel Obstruction. Journal of Nursing Care Quality. 38(1). 69–75.
3.
Madariaga, Ainhoa, Qin Liu, Luisa Bonilla, et al.. (2021). Ethical frameworks in clinical research processes during COVID-19: a scoping review. BMJ Open. 11(7). e047076–e047076. 6 indexed citations
4.
Garg, Swati, Naïri Tchrakian, Blaise Clarke, et al.. (2021). Can TP53 variant negative be high-grade serous ovarian carcinoma? A case series. Gynecologic Oncology Reports. 36. 100729–100729. 1 indexed citations
5.
Karakasis, Katherine, et al.. (2021). Updates on systemic therapy for cervical cancer. The Indian Journal of Medical Research. 154(2). 293–302. 38 indexed citations
6.
McMullen, Michelle, Katherine Karakasis, Robert Rottapel, & Amit M. Oza. (2021). Advances in ovarian cancer, from biology to treatment. Nature Cancer. 2(1). 6–8. 45 indexed citations
7.
8.
Lheureux, Stéphanie, Ana Oaknin, Swati Garg, et al.. (2020). EVOLVE: A Multicenter Open-Label Single-Arm Clinical and Translational Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer after PARP Inhibition Progression. Clinical Cancer Research. 26(16). 4206–4215. 95 indexed citations
9.
Madariaga, Ainhoa, Katherine Karakasis, Pamela Degendorfer, et al.. (2020). Optimizing clinical research procedures in public health emergencies. Medicinal Research Reviews. 41(2). 725–738. 7 indexed citations
10.
Garg, Swati, Michael Cabanero, Qian Tan, et al.. (2019). TP53 mutations in high grade serous ovarian cancer and impact on clinical outcomes: a comparison of next generation sequencing and bioinformatics analyses. International Journal of Gynecological Cancer. 29(2). 346–352. 26 indexed citations
11.
Yang, S.Y. Cindy, Stéphanie Lheureux, Katherine Karakasis, et al.. (2018). Landscape of genomic alterations in high-grade serous ovarian cancer from exceptional long- and short-term survivors. Genome Medicine. 10(1). 81–81. 66 indexed citations
12.
Wilson, Michelle, Michael Friedländer, Stéphanie Lheureux, et al.. (2017). Resisting RECIST—Uniformity Versus Clinical Validity. International Journal of Gynecological Cancer. 27(8). 1619–1627.
13.
Rodríguez-Freixinós, Víctor, Katherine Karakasis, & Amit M. Oza. (2016). New Targeted Agents in Endometrial Cancer: Are We Really Making Progress?. Current Oncology Reports. 18(4). 23–23. 11 indexed citations
14.
Karakasis, Katherine, Julia V. Burnier, Valerie Bowering, Amit M. Oza, & Stéphanie Lheureux. (2016). Ovarian Cancer and BRCA1/2 Testing: Opportunities to Improve Clinical Care and Disease Prevention. Frontiers in Oncology. 6. 119–119. 14 indexed citations
15.
Dhani, Neesha C., Hal W. Hirte, Marcus O. Butler, et al.. (2016). Phase II study of cabozantinib in recurrent/metastatic endometrial cancer (EC): A study of the Princess Margaret, Chicago and California Phase II Consortia.. Journal of Clinical Oncology. 34(15_suppl). 5586–5586. 1 indexed citations
16.
Lheureux, Stéphanie, Patricia A. Shaw, Katherine Karakasis, & Amit M. Oza. (2015). Cancer precursor lesions in the BRCA population at the time of prophylactic salpingo-oophorectomy: Accuracy of assessment and potential surrogate marker for prevention. Gynecologic Oncology. 138(2). 235–237. 6 indexed citations
17.
Lheureux, Stéphanie, Valerie Bowering, Katherine Karakasis, & Amit M. Oza. (2015). Safety evaluation of olaparib for treating ovarian cancer. Expert Opinion on Drug Safety. 14(8). 1305–1316. 14 indexed citations
18.
Wilson, Michelle, Katherine Karakasis, & Amit M. Oza. (2014). Outcomes and endpoints in trials of cancer treatment: the past, present, and future. The Lancet Oncology. 16(1). e32–e42. 151 indexed citations
19.
Wilson, Michelle, Deborah Collyar, Diana T. Chingos, et al.. (2014). Outcomes and endpoints in cancer trials: bridging the divide. The Lancet Oncology. 16(1). e43–e52. 67 indexed citations
20.
Karakasis, Katherine, et al.. (2007). Uncovering a Link between a Plastid Translocon Component and Rhomboid Proteases Using Yeast Mitochondria-Based Assays. Plant and Cell Physiology. 48(4). 655–661. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Eleonora Ghisoni Breakdown of academic impact, for papers by Thomas J. Herzog Breakdown of academic impact, for papers by Marilena Di Napoli Breakdown of academic impact, for papers by Antonella Pietragalla Breakdown of academic impact, for papers by Asima Mukhopadhyay Breakdown of academic impact, for papers by Angela George Breakdown of academic impact, for papers by Katherine C. Kurnit Breakdown of academic impact, for papers by Ainhoa Madariaga Breakdown of academic impact, for papers by Rowan Miller Breakdown of academic impact, for papers by Laure Favier
Rankless by CCL
2026